10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2026)

10x Genomics has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.2 million, down 77.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 77.36% YoY), and the FY2025 annual result was $1.2 million, down 75.4% from the prior year.
• Other Non-Current Liabilities came in at $1.2 million for Q1 2026 at 10x Genomics, down from $1.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.1 million in Q3 2023 to a low of $1.2 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $5.4 million (2025), against an average of $5.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 77.04% in 2023 and sank 77.36% in 2026, its largest moves.
• 10x Genomics' Other Non-Current Liabilities stood at $3.0 million in 2022, then surged by 43.65% to $4.3 million in 2023, then climbed by 17.64% to $5.0 million in 2024, then tumbled by 75.4% to $1.2 million in 2025, then decreased by 1.21% to $1.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.